X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1014) 1014
Publication (147) 147
Conference Proceeding (26) 26
Book / eBook (18) 18
Book Chapter (8) 8
Book Review (7) 7
Patent (4) 4
Dissertation (2) 2
Newsletter (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
natural sciences (338) 338
naturvetenskap (338) 338
physical sciences (336) 336
fysik (334) 334
index medicus (285) 285
humans (266) 266
fusion, plasma and space physics (246) 246
fusion, plasma och rymdfysik (246) 246
male (207) 207
physics, fluids & plasmas (204) 204
female (200) 200
dermatology (146) 146
middle aged (138) 138
psoriasis (125) 125
analysis (123) 123
adult (122) 122
jet (116) 116
nuclear science & technology (114) 114
psoriasis - drug therapy (113) 113
treatment outcome (100) 100
animals (78) 78
aged (70) 70
fusion (70) 70
physics (68) 68
clinical trials (67) 67
tokamak (67) 67
care and treatment (65) 65
safety (65) 65
plasma (64) 64
severity of illness index (64) 64
double-blind method (63) 63
entladung (59) 59
efficacy (58) 58
research (58) 58
deuterium (56) 56
tokamaks (55) 55
transport (54) 54
double-blind (53) 53
plasma physics (53) 53
therapy (49) 49
instruments & instrumentation (48) 48
neutron (48) 48
beryllium (47) 47
tritium (44) 44
antibodies, monoclonal - therapeutic use (43) 43
drug therapy (43) 43
subatomic physics (43) 43
subatomär fysik (43) 43
neurosciences (41) 41
etanercept (40) 40
physics, multidisciplinary (39) 39
dose-response relationship, drug (38) 38
joint european torus (38) 38
nuclear engineering. atomic power (38) 38
patients (38) 38
walls (38) 38
antibodies, monoclonal - adverse effects (37) 37
ustekinumab (36) 36
plasmas (35) 35
erosion (34) 34
medical research (34) 34
moderate (34) 34
research article (34) 34
tungsten (34) 34
health aspects (33) 33
monoclonal antibodies (33) 33
physics, applied (33) 33
properties (33) 33
deposition (32) 32
iter (32) 32
medicine & public health (32) 32
quality-of-life (32) 32
medicine, general & internal (31) 31
pharmacology & pharmacy (31) 31
aged, 80 and over (30) 30
drug administration schedule (30) 30
iter-like wall (30) 30
divertor (29) 29
elektron (29) 29
risk factors (29) 29
adalimumab (28) 28
adolescent (28) 28
article (28) 28
dermatologic agents (27) 27
formulae, receipts, prescriptions (27) 27
abridged index medicus (26) 26
antibodies, monoclonal - administration & dosage (26) 26
cytokines (26) 26
medicine (26) 26
original (26) 26
tokamak devices (26) 26
70 plasma physics and fusion technology (25) 25
confinement (25) 25
dermatologic agents - adverse effects (25) 25
follow-up studies (25) 25
multidisciplinary sciences (25) 25
ringbeschleuniger (25) 25
risk (25) 25
cardiac & cardiovascular systems (24) 24
medicine, experimental (24) 24
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (7) 7
UTL at Downsview - May be requested (5) 5
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Gerstein Science - Stacks (1) 1
OISE - Stacks (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Trinity College (John W Graham) - Stacks (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1035) 1035
Hungarian (29) 29
German (4) 4
Russian (4) 4
French (2) 2
Chinese (1) 1
Japanese (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, ISSN 0190-9622, 03/2017, Volume 76, Issue 3, pp. 405 - 417
Background: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. Objectives: We... 
TO-SEVERE PSORIASIS | scalp psoriasis | USTEKINUMAB | INTERLEUKIN-23 | CYTOKINE | INNATE LYMPHOID-CELLS | guselkumab | adalimumab | efficacy | hand and foot psoriasis | DERMATOLOGY | THERAPY | nail psoriasis | VOYAGE 2 | VOYAGE 1 | psoriasis | safety | SEVERE PLAQUE PSORIASIS | QUALITY-OF-LIFE | LONG-TERM EFFICACY
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 07/2012, Volume 367, Issue 3, pp. 275 - 275
Journal Article
British Journal of Dermatology, ISSN 0007-0963, 09/2018, Volume 179, Issue 3, pp. 615 - 622
Summary Background Short‐term interleukin‐23p19 inhibition by tildrakizumab improves plaque psoriasis and appears to be well tolerated. Objectives Safety and... 
POPULATION | PLACEBO | EFFICACY | ADALIMUMAB | CARDIOVASCULAR EVENTS | USTEKINUMAB | PHASE-III | DOUBLE-BLIND | ANTI-INTERLEUKIN-23 MONOCLONAL-ANTIBODY | ETANERCEPT | DERMATOLOGY | Clinical trials | Mycoses | Psoriasis | Interleukins | Analysis | Gastrointestinal diseases | Monoclonal antibodies | Patient safety | Side effects | Immunotherapy
Journal Article
British Journal of Dermatology, ISSN 0007-0963, 05/2019, Volume 180, Issue 5, pp. 1039 - 1049
Summary Background Long‐term evaluation is required to confirm the safety profile of newer biologic agents. Objectives To report on pooled safety data from the... 
LONGITUDINAL ASSESSMENT | EFFICACY | ADALIMUMAB TREATMENT | USTEKINUMAB | IXEKIZUMAB | LONG-TERM SAFETY | SEVERE PLAQUE PSORIASIS | PHASE-III | DOUBLE-BLIND | MONOCLONAL-ANTIBODY | DERMATOLOGY | Complications and side effects | Care and treatment | Safety regulations | Safety and security measures | Psoriasis | Analysis | Melanoma | Adalimumab | Skin cancer | Clinical trials | Monoclonal antibodies | Safety | Patients
Journal Article
British Journal of Dermatology, ISSN 0007-0963, 08/2018, Volume 179, Issue 2, pp. 320 - 328
Summary Background Biologics are being used increasingly to treat moderate‐to‐severe psoriasis. Efficacy may differ in patients with previous exposure to... 
DRUG SURVIVAL | RATES | THERAPIES | ETANERCEPT | REGISTRY | DERMATOLOGY | Complications and side effects | Medical research | Care and treatment | Psoriasis | Analysis | Clinical trials | Medicine, Experimental | Patient safety | Side effects | Patients | Immunotherapy
Journal Article